Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun.319:1281–1286. [DOI] [PubMed] [Google Scholar] · DOI
Cited by
Items 601–700 of 954
Priol, A.-C., Denis, L., Boulanger, G., Thépaut, M., Geoffray, M., & Tordjman, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179464 · Cited by 13
“Numerous data across the literature suggest hypofunctioning of the glutamatergic system via NMDA receptor hypofunction in schizophrenia [122].”
Siddik, M. A. B., & Fendt, M. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113961 · Cited by 13
Infectious agents are associated with psychiatric diseases
Krause, D., Weidinger, E., Matz, J., Wildenauer, A., Wagner, J. K., Obermeier, M., Riedel, M. J., Möller, H., & Müller, N. (2012) · Mental Illness · doi:10.4081/mi.2012.e10 · Cited by 14
Phosphodiesterase inhibitors—Are they potential neuroleptic drugs?
Becker, A., & Grecksch, G. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.08.002 · Cited by 12
Skrzypińska, D., & Szmigielska, B. (2013) · Archives of Psychiatry and Psychotherapy · doi:10.12740/app/18443 · Cited by 13
Verbal working memory and functional large-scale networks in schizophrenia
Dauvermann, M. R., Moorhead, T. W. J., Watson, A. R., Duff, B. J., Romaniuk, L., Hall, J., Roberts, N., Lee, G. L., Hughes, Z. A., Brandon, N. J., et al. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.10.004 · Cited by 12
“However it has been established that glutamatergic and dopaminergic alterations in the PFC (Coyle, 2006; Kantrowitz and Javitt, 2010; Laruelle, 2014), midbrain (Abi-Dargham et al.”
InfluentialPopiolek, M., Tierney, B., Steyn, S. J., & DeVivo, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00229 · Cited by 13
Гареева, А. Э., Закиров, Д. Ф., & Хуснутдинова, Э. К. (2013) · Генетика · doi:10.7868/s001667581308002x · Cited by 11
Theories of consciousness and psychiatric disorders – A comparative analysis
Stefanelli, R. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105204 · Cited by 15
“R. Stefanelli Neuroscience and Biobehavioral Reviews 152 (2023) 105204 Notably, such hypotheses seem to be supported by several neuroimaging (Charles et al., 2017; Carter et al., 2001; Foti et al., 2012) and molecular (Coyle, 2006) findings.”
BackgroundFarmer, C. B., Roach, E. L., Bice, L. R., Falgout, M. E., Mata, K. G., Roche, J. K., & Roberts, R. C. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02650-5 · Cited by 12
“1998, 2000; Howes and Kapur 2009), glutamate (Javitt 2004; Coyle 2006; Hutcheson et al. 2012; Roberts et al. 2022), GABA (Lewis 2000a, 2000b), and serotonin (Meltzer 1989; Remington 2008).”
BackgroundTowards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies
Kositsyn, Y. M., de Abreu, M. S., Kolesnikova, T. O., Lagunin, A. A., Poroikov, V., Harutyunyan, H. S., Yenkoyan, K. B., & Kalueff, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119482 · Cited by 12
“The pathogenesis of schizophrenia involves multiple neurochemical deficits, especially within the glutamate-, GABA- and monoaminergic signaling systems [2,17,18] (Figure 1).”
BackgroundUsing Ketamine to Model Semantic Deficits in Schizophrenia
Neill, E., Rossell, S. L., McDonald, S., Joshua, N. R., Jansen, N., & Morgan, C. J. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318234ee1e · Cited by 11
Duration of untreated negative symptoms and duration of active negative symptoms: proof of concepts
Murphy, B., Stuart, A. H., & McGorry, P. D. (2008) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2007.00053.x · Cited by 14
An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter
Lowe, J. A., III, DeNinno, S. L., Drozda, S. E., Schmidt, C. J., Ward, K. M., Tingley, F. D., Sanner, M. A., Tunucci, D., & Valentine, J. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.071 · Cited by 11
Structural correlates of cognitive deficit and elevated gamma noise power in schizophrenia
Suazo, V., Díez, Á., Montes, C., & Molina, V. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12120 · Cited by 13
“Gamma band alterations have been reported in schizophrenia,(5) possibly through GABA hypofunction,(6) which may also contribute to structural alterations in schizophrenia.(7) Noise power is among the gamma-related measurements previously used in schizophrenia literature and it is defined as the amount of background os…”
BackgroundMouse Mutagenesis and Disease Models for Neuropsychiatric Disorders
Gondo, Y., Murata, T., Makino, S., Fukumura, R., & Ishitsuka, Y. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_106 · Cited by 11
“N-methyl-D-aspartate receptors (NMDAR) may be involved in the pathophysiology of schizophrenia, implicated by the association of the reduction in NMDARmediated signaling pathways, particularly D-serine deficiency, with the disorder (Coyle 2006).”
BackgroundXiang, J., Ma, C., Chen, X., & Cheng, C. (2025) · Brain Sciences · doi:10.3390/brainsci15020179 · Cited by 11
“This aligns with gene expression findings pointing to the involvement of glutamate-related pathways in connectivity gradient differences [60,65].”
Impact of D-Amino Acids in Schizophrenia
Dursun, S. M., Dursun, L. H., & Baker, G. B. (2025) · Biomolecules · doi:10.3390/biom15091270 · Cited by 10
Mayer, J. S., Stäblein, M., Oertel‐Knöchel, V., & Fiebach, C. J. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00202 · Cited by 11
Huang, L.-C., Lin, S., Tseng, H., Chen, K. C., & Yang, Y. K. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110159 · Cited by 12
Strauss, G. P. (2023) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-023-02556-3 · Cited by 11
Adams, W. K., Halberstadt, A. L., & van den Buuse, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00109 · Cited by 10
“Interactions between the glutamate system and the dopamine or serotonin systems have been widely studied in this context (Aghajanian and Marek, 2000; Svensson, 2000; Coyle, 2006; Meltzer et al., 2011).”
BackgroundInfluentialA Structure-Function Mechanism for Schizophrenia
Vadakkan, K. I. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00108 · Cited by 11
“…antagonism leads to schizophrenia-like symptoms N -methyl-d-aspartate receptor antibody encephalitis induced by auto-antibodies to NR1/NR2B heteromers of the NMDA receptors manifests as severe memory defects and schizophrenia-like symptoms of hallucinations (Coyle, 2006; Dalmau et al., 2008).”
BackgroundInfluentialWang, J., Zhang, B., Zhang, M., Chen, J., Deng, H., Wang, Q., & Sun, X. (2017) · Neuropsychobiology · doi:10.1159/000480514 · Cited by 10
Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed
González-Rodríguez, A., Guàrdia, A., Palao, D. J., Labad, J., & Seeman, M. V. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i4.34 · Cited by 10
Tetrahydrobiopterin and Its Multiple Roles in Neuropsychological Disorders
Midhun, T., Krishna, S. S., & WILSON, S. K. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03543-x · Cited by 12
“They demonstrated that elevated blood levels of BH4 alleviate schizophrenia's negative and cognitive symptoms and that changes in the levels and function of this cofactor may play a role in the pathogenesis of schizophrenia [35, 36].”
BackgroundRosalinda, C., Joy, K., Shahza, M., & Robert, R. (2012) · InTech eBooks · doi:10.5772/31396 · Cited by 12
“The glutamatergic system is heavily implicated in schizophrenia and examining possible aberrant circuitry or lack of plasticity may provide new insights into treatment options (Coyle 2006; Goff & Coyle 2001; Javitt 2004; Krystal 2008).”
BackgroundThe audacity of proteomics: a chance to overcome current challenges in schizophrenia research
Baloyianni, N. V., & Tsangaris, G. T. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.85 · Cited by 12
The effect of G72 genotype on neural correlates of memory encoding and retrieval
Jansen, A., Krach, S., Krug, A., Markov, V., Thimm, M., Paulus, F. M., Zerres, K., Stöcker, T., Shah, N. J., Nöthen, M. M., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.018 · Cited by 10
“This provides a potential link between G72 and the glutamate hypofunction hypothesis of schizophrenia (Coyle, 2006).”
Chiusaroli, R., Garofalo, P., Espinoza, S., Neri, E., Caselli, G., & Lanza, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.010 · Cited by 10
Jones, C. K., Sheffler, D. J., Williams, R. D., Jadhav, S. B., Felts, A. S., Morrison, R. D., Niswender, C. M., Daniels, J. S., Conn, P. J., & Lindsley, C. W. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.013 · Cited by 10
Clinical utility of serum biomarkers for major psychiatric disorders
van Beveren, N. J. M., & Hoogendijk, W. J. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00014-6 · Cited by 11
Dormann, O.-D., Schuelert, N., & Rosenbrock, H. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02455-w · Cited by 9
“Therefore, there is a high clinical need to develop treatments that target network dysfunction, for example, the excitatory–inhibitory (E/I) balance involving mainly the glutamatergic and GABAergic systems [2, 3].”
BackgroundRecent Developments in Glycine Transporter-1 Inhibitors
Cioffi, C. L., Liu, S., & Wolf, M. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45002-2 · Cited by 9
Matrov, D., Imbeault, S., Kanarik, M., Školnaja, M., Schikorra, P., Miljan, E., Shimmo, R., & Harro, J. (2020) · Acta Histochemica · doi:10.1016/j.acthis.2020.151531 · Cited by 9
Srivastav, S., Cui, X., Varela, R. B., Kesby, J. P., & Eyles, D. W. (2023) · Schizophrenia · doi:10.1038/s41537-023-00397-2 · Cited by 11
“Other neurotransmitters such as glutamate are also implicated in schizophrenia 17,18 .”
BackgroundMacKenzie, E. M., Fassihi, A., Davood, A., Chen, Q., Rauw, G., Rauw, G. A., Knaus, E. E., & Baker, G. B. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.027 · Cited by 9
Rojas, C. J., Alt, J., Ator, N. A., Wilmoth, H., Rais, R., Hin, N., DeVivo, M., Popiolek, M., Tsukamoto, T., & Slusher, B. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652586 · Cited by 9
“These findings have led to the hypothesis that hypofunction of the NMDA receptor may contribute to the disorder (Coyle, 2006; Javitt et al., 2001) and that potentiation of receptor function may help alleviate schizophrenia symptoms (Yang and Svensson, 2008).”
BackgroundA case of GABAR antibodies in schizophrenia
Haussleiter, I. S., Wandinger, K., & Juckel, G. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1157-2 · Cited by 9
“The described psychomimetic effects of NMDA antagonists have been attributed to pre-synaptic functional receptor blocking in thalamus and frontal cortex, causing a decreased Gamma-aminobutyric acid (GABA) release [5].”
BackgroundKnytl, P., Voráčková, V., Dorazilová, A., Rodríguez, M., Cvrčková, A., Kofroňová, E., Kuchař, M., Kratochvílová, Z., Šustová, P., Čerešňáková, S., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00390 · Cited by 9
Jimenez, N. T., Lines, J., Kueppers, R. B., Kofuji, P., Wei, H. G., Rankila, A., Coyle, J. T., Miller, R. F., & McLoon, L. K. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.2.16 · Cited by 9
“85 As a result, we recommend evaluating a wider range of flash intensities under photopic, scotopic, and mesopic background adaptation to evaluate distinct retinal pathways in subjects with schizophrenia in comparison with controls.”
Self-citationAnti-N-methyl-D-aspartate-receptor antibody encephalitis combined with syphilis: A case report
Li, X.-Y., Shi, Z., Guan, Y., & Ji, Y. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i12.2603 · Cited by 9
Tran, H., Park, S. J., Shin, E., Tran, T.-V., Sharma, N., Lee, Y. J., Jeong, J. H., Jang, C., Kim, D.-J., Nabeshima, T., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118795244 · Cited by 9
“In addition, repeated PCP treatment caused dis-inhibition of glutamatergic activity and increased excitatory transmission in the PFC of rodents and nonhuman primates, leading to schizophrenia-like symptoms (Coyle, 2006; Takahata and Moghaddam, 2003; Noda et al., 2001).”
BackgroundServaes, S., Kara, F., Glorie, D., Stroobants, S. G., der Linden, A. V., & Staelens, S. G. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252635 · Cited by 9
“…as depression, anxiety, and more recently obsessive compulsive disorder (OCD), the emerging role of glutamate signaling has been garnering interest (Coyle, 2006; Pittenger et al., 2011; This work was supported by a DocPro from the University of Antwerp [41/FA020000/FFB140317] and the Fonds…”
Phosphorylation Induces Conformational Rigidity at the C-Terminal Domain of AMPA Receptors
Chatterjee, S., Ade, C., Nurik, C. E., Carrejo, N. C., Dutta, C., Jayaraman, V., & Landes, C. F. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b10749 · Cited by 9
Sasidharan, A., Kumar, S., John, J. P., Philip, M., Subramanian, S., Jain, S., & Kutty, B. M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.03.034 · Cited by 9
Translational neuroimaging : tools for CNS drug discovery, development and treatment
McArthur, R. A. (2012) · Cited by 10
Pecsok, M. K., Robinson, H., Atkins, A., Calkins, M. E., Elliott, M. A., Mordy, A. E., Stifelman, J., Gur, R. C., Moberg, P. J., Nanga, R. P. R., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1535158 · Cited by 8
“…in the mammalian brain—is considered critical given its ubiquitous role in brain function ranging from cellular energetics to high-order cognitive functions (Coyle, 2006; Curtis and Johnston, 1974; Erecińska and Silver, 1990; McEntee and Crook, 1993; Roalf et al., 2020; Robbins and Murphy, 2006).”
Górny, M., Bilska‐Wilkosz, A., Iciek, M., Rogóż, Z., & Lorenc‐Koci, E. (2023) · FEBS Journal · doi:10.1111/febs.16944 · Cited by 10
Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology
O’Tuathaigh, C. M. P., Desbonnet, L., Moran, P. M., & Waddington, J. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_194 · Cited by 8
Neurochemical Oscillations in the Basal Ganglia
Noori, H. R., & Jäger, W. (2009) · Bulletin of Mathematical Biology · doi:10.1007/s11538-009-9441-7 · Cited by 10
A Gene-Based Analysis of Acoustic Startle Latency
Smith, A. K., Jovanović, T., Kilaru, V., Lori, A., Gensler, L., Lee, S. S., Norrholm, S. D., Massa, N., Cuthbert, B. N., Bradley, B., et al. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00117 · Cited by 9
The GluA1 AMPAR subunit is necessary for hedonic responding but not hedonic value in female mice
Strickland, J. A., Austen, J. M., Sprengel, R., & Sanderson, D. J. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113206 · Cited by 8
Antipsychotic-like effect of ethyl acetate fraction of Terminalia macroptera leaf in mice
Ior, L. D., Otimenyin, S. O., & Okwuasaba, F. K. (2021) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2021.01.003 · Cited by 8
“The negative symptoms of schizophrenia is a crucial feature of the disorder (Coyle, 2006).”
BackgroundThe Neurobiology of Schizophrenia
Bobo, W. V., Rapoport, J. L., Abi‐Dargham, A., Fatemi, S. H., & Meltzer, H. Y. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch19 · Cited by 9
Brown, J., Grayson, B., Neill, J. C., Harte, M., Wall, M. J., & Ngomba, R. T. (2023) · Cells · doi:10.3390/cells12060919 · Cited by 8
“Current research is moving away from the dopaminergic hypothesis of schizophrenia, and there is now mounting evidence that glutamatergic aberrations may contribute to those symptoms that are resistant to antipsychotic medications [11,12].”
BackgroundGil‐Ad, I., Portnoy, M., Tarasenko, I., Bidder, M., Kramer, M., Taler, M., & Weizman, A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.009 · Cited by 8
“Evidence accumulated in recent years suggests that schizophrenia and bipolar disorders are associated with disturbance in γ-aminobutyric-acid (GABA) and glutamate transmission in the brain (Coyle, 2006; Kugaya and Sanacora, 2005) as well.”
BackgroundSteward, L. J., Kennedy, M. D., Morris, B., & Pratt, J. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.016 · Cited by 8
“Based upon accumulating evidence to support a glutamate hypofunction hypothesis of schizophrenia (Jentsch and Roth, 1999; Coyle, 2006), we employed repeated treatment with a low dose of the psychotomimetic non competitive NMDA receptor antagonist phencyclidine (PCP), a schizophreniarelated animal…”
Schulz, S., Arning, L., Pinnow, M., Epplen, J. T., & Beste, C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.024 · Cited by 9
“In this context, changes in NMDA receptor mediated glutamatergic neurotransmission were observed in patients with schizophrenia (e.g. Cherlyn et al., 2010; Coyle, 2006; Goff and Coyle, 2001; Marsman et al., in press; Quin et al., 2005), where disturbed functioning of the glutamatergic system has been reported with the…”
Yao, L., Wang, Z., Deng, D., Yan, R., Ju, J., & Zhou, Q. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2306-1 · Cited by 9
Sheffler, D. J., Nedelcovych, M. T., Williams, R. D., Turner, S. C., Duerk, B. B., Robbins, M. R., Jadhav, S. B., Niswender, C. M., Jones, C. K., Conn, P. J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.011 · Cited by 8
Consciousness, Memory, and Hallucinations
Behrendt, R. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0959-5_3 · Cited by 9
Emergency Department Presentations of Anti–N-Methyl-D-Aspartate Receptor Encephalitis
Abe, K. K., Koli, R. L., & Yamamoto, L. G. (2016) · Pediatric Emergency Care · doi:10.1097/pec.0000000000000713 · Cited by 9
Gallant, S., Welch, L., Martone, P., & Shalev, U. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.004 · Cited by 10
“Other NMDA receptor antagonists, such as ketamine and MK-801 have been shown to also induce psychosis and cognitive deficits closely resembling symptoms of schizophrenia [7].”
17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats
Holter, K. M., Klausner, M. G., Hite, M. H., Moriarty, C., Barth, S. H., Pierce, B. E., Iannucci, A. N., Sheffler, D. J., Cosford, N. D. P., Bimonte‐Nelson, H. A., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02996-0 · Cited by 7
“N -methyl-D-aspartate receptor (NMDAR) hypofunction contributes to pathophysiology of schizophrenia, and this is supported by fi ndings that pharmacological blockade of NMDARs induces psychotomimetic-like effects and cognitive dysfunction in humans and animals [20, 21].”
Landreth, K., Simanaviciute, U., Fletcher, J., Grayson, B., Grant, R. A., Harte, M., & Gigg, J. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211003199 · Cited by 9
“Our chosen model was the sub-chronic phencyclidine (scPCP) treated rat, developed to model the N-methyl-D-aspartate (NMDA) receptor hypofunction hypothesis of schizophrenia (Steinpreis, 1996; Krystal et al., 1994; Javitt and Zukin, 1991; Coyle, 2006).”
MethodAxonal transport deficits in neuropsychiatric disorders
Badal, K. K., & Puthanveettil, S. V. (2022) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2022.103786 · Cited by 8
Romero-Núñez, E., Ayala, T. B., Cervantes, G. I. V., Roldán-Roldán, G., González‐Esquivel, D. F., Muñiz‐Hernández, S., Salazar, A., Armenta, M. M., Gómez‐Manzo, S., González-Conchillos, H., et al. (2022) · Cells · doi:10.3390/cells11233819 · Cited by 7
The DAOA gene is associated with schizophrenia in the Taiwanese population
Chu, C., Chow, P. C., Cohen‐Woods, S., Gaysina, D., Tang, K., & McGuffin, P. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.03.013 · Cited by 7
“As such, this provides an important potential pathogenic link between DAOA, DAO, and the glutamate hypofunction hypothesis of schizophrenia (Coyle, 2006).”
BackgroundTodd, J., Salisbury, D. F., & Michie, P. T. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.144 · Cited by 11
Okusaga, O. O. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.01.011 · Cited by 8
Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?
Shim, S. S., & Nadeem, R. N. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.007 · Cited by 7
Özdemir, O., & Özdemir, P. G. (2016) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.253445 · Cited by 10
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
A New Case of the Rare 10q22.3q23.2 Microdeletion Flanked by Low-Copy Repeats 3/4
Molck, M. C., Simioni, M., Vieira, T. P., Monteiro, F. P., & Gil‐da‐Silva‐Lopes, V. L. (2017) · Molecular Syndromology · doi:10.1159/000469965 · Cited by 7
“In addition, this gene has also been associated with schizophrenia in several studies [Fallin et al., 2005; Coyle, 2006; van Bon et al., 2011].”
Regulation of Dietary Amino Acids and Voltage-Gated Calcium Channels in Autism Spectrum Disorder
Singh, S., Sangam, S. R., & Rajagopal, S. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-30402-7_24 · Cited by 8
Romei, C., Luccini, E., Raiteri, M., & Raiteri, L. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.12.004 · Cited by 7
Analysis of a Promoter Polymorphism in the SMDF Neuregulin 1 Isoform in Schizophrenia
Pedrosa, E., Nolan, K. A., Stefanescu, R. N., Hershcovitz, P., Novák, T., Žukov, I., Stopková, P., & Lachman, H. M. (2009) · Neuropsychobiology · doi:10.1159/000223732 · Cited by 9
Correction: Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/annotation/805ba3f5-0fd7-41f9-bc2c-31ebf507f05b · Cited by 7
Thelagathoti, R. K., Tom, W. A., Chandel, D. S., Jiang, C. Q., Krzyzanowski, G. D., Olou, A. A., & Fernando, M. R. (2025) · Biomolecules · doi:10.3390/biom15070963 · Cited by 7
Biagianti, B., Bigoni, D., Maggioni, E., & Brambilla, P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.006 · Cited by 6
Gowda, V. K., Vignesh, S., Natarajan, B., & Shivappa, S. K. (2021) · Journal of Pediatric Neurosciences · doi:10.4103/jpn.jpn_80_20 · Cited by 7
Gassó, P., Martínez-Pinteño, A., Rodríguez, N., Madero, S., Gómez, M., Segura, À. G., García‐Rizo, C., Morén, C., Mas, S., & Parellada, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032054 · Cited by 6
“In recent decades, this has led to the glutamate (GLU) hypothesis, which also plays a key role in schizophrenia pathophysiology, particularly in the development of negative symptoms and cognitive dysfunction [2,3].”
BackgroundTang, Y., Tan, Y., Palaniyappan, L. K., Yao, Y., Luo, Q., & Li, Y. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230099 · Cited by 6
“52 More specifically, hypoactivity of SRC can lead to hypofunction of NMDA receptors in mice models of schizophrenia, 53 consistent with postmortem brain studies from human patients.”
Alteration of microRNA expression in lymphocytes in patients with first-episode schizophrenia
Huang, J., & Wang, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06659-w · Cited by 6
“The hyperactive dopaminergic function related to SCZ may also be caused by dysregulated n-Methyl-d-Aspartic Acid (NMDA) receptors neurotransmission [51].”
Shen, J., Li, X., Zhong, Y., Zhang, J., Qin, H., Chen, F., & Zhao, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1551172 · Cited by 6
“Aberrant glutamatergic signaling is recognized as a key driver of disease etiology, with multiple studies reporting signi fi cant alterations in glutamate and related amino acids in both blood and cerebrospinal fl uid (56, 57).”
The Role of Astrocytes in the Pathophysiology of Schizophrenia.
Steffek, A. E. (2007) · Deep Blue (University of Michigan) · Cited by 6
Metabotropic glutamate receptor function and regulation of sleep-wake cycles
Holter, K. M., Pierce, B. E., & Gould, R. W. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2022.11.002 · Cited by 8
Maness, E. B., Blumenthal, S. A., & Burk, J. A. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114497 · Cited by 7
Timpe, J. M., Wang, C. Z., Kim, J.-S., & Johnson, K. M. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23446 · Cited by 7
Urabe, H., Miyakoshi, N., Ohtake, N., Nozoe, A., Ochi, M., Fukasawa, M., Kinoshita, K., Yamaguchi, J.-I., Marumo, T., Hikichi, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112521 · Cited by 6
McNamara, R. K. (2009) · Clinical Lipidology · doi:10.2217/clp.09.62 · Cited by 7
Modulation of glycine sites enhances social memory in rats using PQQ combined with d-serine
Zhou, X., Liu, D., Zhang, R., Peng, Y., Qin, X., & Mao, S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.04.034 · Cited by 6
Torres‐Carmona, E., Ueno, F., Iwata, Y., Nakajima, S., Song, J., Mar, W., Abdolizadeh, A., Agarwal, S. M., Luca, V. D., Remington, G. J., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.05.002 · Cited by 6
Singer, P., & Yee, B. K. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1389718 · Cited by 6
“The glutamate hypofunction hypothesis of schizophrenia (Carlsson and Carlsson, 1990; Olney and Farber, 1995; Olney et al., 1999; Coyle, 2006; Moghaddam and Javitt, 2012; Coyle et al., 2020) has been highly influential in the search of novel drugs for the treatment of negative and cognitive…”
BackgroundPan, W. Q., Li, T., Ma, X., & Huo, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06530-y · Cited by 7
“…neuroplasticity [15], with perturbations in γ-aminobutyric acid (GABA) and glutamate neurotransmission, and dysfunction in the N-methyl-D-aspartate receptor (NMDAR)/glutamate system, situated amidst primary and secondary glutamatergic neurons, may underlie the pathology of schizophrenia [16, 17].”
Electrophysiological Deficits in Schizophrenia: Models and Mechanisms
von Reyn, C. R., Michael, E., Freedman, R., Valerie, M., Michael, J., Chinn, G. A., & Steven, J. (2011) · InTech eBooks · doi:10.5772/27511 · Cited by 6
“Considerable evidence implicates reduced glutamatergic N-methyl-D-aspartate receptor (NMDAR) mediated signaling as the core pathophysiologic deficit of schizophrenia (i.e., the Glutamate Hypothesis) (Goff and Coyle, 2001, Coyle, 2006).”
Background‘Why, why did you have me treated?’: the psychotic experience in a literary narrative: Figure 1
Kaptein, A. A., Koopman, J. J. E., Weinman, J. A., & Gosselink, M. J. (2011) · Medical Humanities · doi:10.1136/jmh.2010.006270 · Cited by 5
“2 Papers on brain chemistry, on schizophrenia as ‘a glutamate disorder ’ or on ‘aberrant brain activation during a working memory task in psychotic major depression’ are just a few examples of this biomedical dominance.(3) 4 A recent editorial in JAMA even maintained that empathy in medicine has a neurobiological basi…”
BackgroundAnti-NMDA Receptor Encephalitis
Kang, J. H., Lee, S. H., Shin, J. W., Ahn, M. Y., Baek, S. H., Lee, H. S., Kim, J. S., Shin, D. I., & Lee, S. S. (2011) · Journal of the Korean Neurological Association · Cited by 6
Schizophrenia in the 21st Century
Burne, T. H. J. (2012) · InTech eBooks · doi:10.5772/1669 · Cited by 5
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.